Global life sciences AI · Published 16 November 2026 · HERMS Consultancy DMCC
Discover the HERMS life sciences platform and our regulatory affairs expertise.
Global pharmaceutical market access connects clinical evidence to the decisions that determine reimbursement, price and practical availability. A credible strategy demonstrates benefit against relevant alternatives, translates that benefit into locally appropriate economic evidence, explains uncertainty and tests affordability. Regulatory authorization is not the same as funded access. Build a reusable evidence core, then adapt comparators, patient populations, models, budgets and submission requirements to each decision-maker rather than treating one global value dossier as a universally acceptable reimbursement submission. Joint clinical assessments for medicinal products NICE technology appraisal and highly specialised technologies guidance: the manual Reimbursement Review Reports Section 3 Economic evaluation
Market access is a chain of decisions—not a launch milestone
A medicine may be authorized, assessed, priced, listed and purchased through different institutions and processes. Even a positive reimbursement decision may specify a narrower population, treatment sequence, prescriber or service setting than the authorized indication. Access planning therefore needs to identify the decision, institution, evidence and operational dependency at every stage.
Health technology assessment, or HTA, synthesizes evidence concerning the consequences of a technology. It can encompass clinical, economic, organizational, social and ethical considerations. Its role and decision authority vary: an HTA recommendation is not automatically a negotiated price, procurement award or individual patient entitlement. Overview — Health Technology Assessment Transparency Committee Reimbursement Review Reports
| Decision | Principal question | Evidence/implementation focus |
|---|---|---|
| Regulatory authorization | Does the product meet applicable quality, safety and efficacy standards? | Regulatory dossier and authorized indication |
| Comparative clinical assessment | How does it perform relative to relevant alternatives? | Comparator, population, outcomes and uncertainty |
| Economic assessment | Do added outcomes justify additional resource use? | Local perspective, model and sensitivity analysis |
| Pricing / contracting | What commercial terms are acceptable within the applicable system? | Evidence-supported scenarios and legally compliant terms |
| Funding / formulary | Who is covered and under what conditions? | Eligibility, restrictions and budget consequences |
| Procurement / delivery | Can funded treatment be purchased and delivered? | Supply, service capacity, contracts and accountable implementation |
Begin with the target decision problem
Define population, intervention, comparator and outcomes—PICO—before finalizing the evidence plan. Include treatment line, biomarkers, prior therapies, care setting, follow-up and intended claim. A trial comparator suitable at protocol development may no longer represent local practice when the submission is reviewed. NICE technology appraisal and highly specialised technologies guidance: the manual 4 Economic evaluation
Maintain a living decision matrix across priority markets. For each, record the competent authority or payer, assessment route, clinical comparator, accepted endpoints, economic perspective, price basis, budget requirements and current source. Separate confirmed requirements from assumptions and questions for advice. The matrix is a proposed planning tool, not evidence that every market follows one pathway.
Engage relevant scientific and HTA advice early enough to affect trial design, endpoint collection and comparative evidence. Advice does not guarantee a favorable outcome, and requirements may evolve as competitors enter the market. Record the advice, date, scope and resulting development decisions.
Connect clinical value to relevant comparative evidence
An access claim should identify the patient-relevant outcome, comparator, magnitude of effect, precision and limitations. Survival, symptoms, functioning, adverse events and quality of life can matter in different ways. Statistical significance alone does not establish clinically meaningful added value or justify a price premium. 4 Economic evaluation Benefit Assessment of Medicinal Products Transparency Committee
Direct randomized comparisons can provide strong relative-effect evidence when they address the decision problem. When they do not, assess systematic review, network meta-analysis or other justified comparisons. These methods have assumptions about comparability, effect modifiers and evidence structure; they do not create missing randomized evidence. Avoid presenting a cross-trial difference as a causal head-to-head result.
Treat surrogate endpoints and immature survival data explicitly. If a model predicts long-term benefit from an intermediate outcome, explain and support the relationship in the relevant disease and population. NICE emphasizes that surrogate validation is context-specific and that extrapolation requires justification and uncertainty analysis. 4 Economic evaluation
Build an uncertainty register before negotiating price
| Uncertainty | Why it matters | Proposed response |
|---|---|---|
| Relative clinical effect | Comparator or evidence does not match the local question | Early advice; additional comparison; narrower claim |
| Durability | Long-term benefit exceeds observed follow-up | Alternative extrapolations; follow-up plan; explicit waning scenarios |
| Generalizability | Trial participants differ from treated patients | Applicability assessment and fit-for-purpose RWE |
| Utilities / quality of life | Health-state values materially affect results | Appropriate instruments, current local methods and sensitivity analysis |
| Resource use | Care pathways differ across countries | Local validation of utilization and unit costs |
| Eligible population / uptake | Budget consequences depend on who actually receives therapy | Transparent population funnel and uptake scenarios |
| Implementation | Capacity or diagnostics constrain access | Service-readiness and operational planning |
Separate parameter uncertainty from structural uncertainty and patient heterogeneity. Varying a few inputs does not test whether the model structure is appropriate. Show which assumptions change the decision, what further evidence could resolve them, and whether that evidence can be generated within a useful timeframe. 4 Economic evaluation Section 3 Economic evaluation
Economic value is not the same as affordability
Cost-effectiveness compares incremental costs with incremental outcomes. In a cost-utility analysis, health outcomes may be expressed as quality-adjusted life years, or QALYs. An incremental cost-effectiveness ratio, ICER, divides the difference in costs by the difference in effects. Interpret it within the applicable decision framework; there is no single global QALY threshold. 4 Economic evaluation Section 3 Economic evaluation
A model should match the disease process and decision problem, with justified structure, horizon, treatment effects, resource use and utility inputs. Validate calculations and clinical predictions; document sources and changes. A previously accepted model is not automatically appropriate for a new indication or country. 4 Economic evaluation
Affordability asks a different question: what happens to the payer’s budget over a relevant planning period? A therapy can offer attractive value per patient while creating a substantial total budget requirement because many patients are eligible. Conversely, a small budget impact does not prove cost-effectiveness. PBAC separates economic evaluation from use-in-practice and budget analyses. Section 3 Economic evaluation Section 4 Use of the medicine in practice
Build a budget impact model that can be challenged
Start with a population funnel: covered population → disease prevalence/incidence → diagnosed patients → eligible treatment group → funded/reachable patients → expected treated patients. Specify timing, prevalent versus incident cohorts and discontinuation. Avoid multiplying broad prevalence by an optimistic uptake percentage without checking the treatment pathway.
Compare a current-care scenario with a scenario including the medicine. Include relevant acquisition, administration, monitoring, adverse events and displaced care within the chosen budget perspective. Align uptake and treatment duration with the requested position in therapy. Do not count cost offsets twice or assume a reduced clinical event automatically releases cash from a fixed-capacity service. Section 4 Use of the medicine in practice
Keep price basis explicit: list, modeled net or confidential scenario. Specify currency, year, taxes, discounts and unit conversions. Use scenario ranges for population, uptake, persistence, treatment mix and price. The output should be a transparent decision aid, not a single persuasive total with hidden assumptions. 4 Economic evaluation Section 4 Use of the medicine in practice
Global evidence needs country-specific adaptation
The following comparison is selective, not an exhaustive global rulebook. Verify current local procedures, product-specific scope and submission templates before relying on it.
| Market / framework | What is assessed or decided | Localization priority / limitation |
|---|---|---|
| European Union JCA | Shared analysis of relative clinical effects; supports national HTA | Does not set one EU price or reimbursement decision; retain national work |
| England — NICE | Clinical and economic evidence within NICE appraisal methods | Current scope, reference case, uncertainty and NHS resource perspective |
| Germany — G-BA / AMNOG | Additional benefit versus an appropriate comparator | Comparator and patient-relevant outcomes; distinguish benefit assessment from negotiation |
| France — HAS Transparency Committee | SMR and ASMR inform reimbursement and pricing | Clinical benefit versus added value; opinion is not the final ministerial decision |
| Canada — CDA-AMC | Clinical/cost-effectiveness and perspectives inform nonbinding recommendations | Participating public plans, local requirements and Quebec distinction |
| Australia — PBAC / PBS | Comparative clinical/economic case and financial implications | Requested listing, main comparator, use in practice and budget estimates |
| United States — selected Medicare program | CMS negotiates MFPs for selected drugs under defined statutory rules | Not universal US HTA or a single price for all payers/products |
EU joint clinical assessments began applying to new cancer medicines and ATMPs from 12 January 2025. They analyze relative clinical effects and support national processes; they do not eliminate country-specific economic, pricing or reimbursement decisions. A shared evidence package still needs a national access strategy. Joint clinical assessments for medicinal products Overview — Health Technology Assessment
In Germany, the G-BA assesses additional benefit versus the appropriate comparator, with IQWiG able to support assessment. In France, HAS distinguishes clinical benefit, SMR, from clinical added value, ASMR; its opinion informs subsequent decisions and pricing. Neither system should be reduced to a universal cost-per-QALY rule. Benefit Assessment of Medicinal Products Transparency Committee
CDA-AMC describes its reimbursement recommendations as nonbinding and relevant to participating public governments excluding Quebec. PBAC’s methods explicitly connect the clinical place in therapy with economic and budget analyses. Preserve these institutional differences in the submission plan instead of translating only the currency. Reimbursement Review Reports Section 3 Economic evaluation Section 4 Use of the medicine in practice
The first cycle of CMS negotiated Maximum Fair Prices for selected Medicare Part D drugs took effect on 1 January 2026. This is a defined program, not evidence that CMS sets prices for all medicines or that the US has one national HTA-based reimbursement process. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026
Use current methods—not a recycled country template
Maintain a source-controlled country requirements register with access dates, owner and review triggers. NICE’s manual was updated on 13 October 2026. Review the current NICE manual and any applicable methods notices before selecting utility methods. NICE technology appraisal and highly specialised technologies guidance: the manual
A practical localization checklist covers comparator and patient subgroups; clinical endpoints; economic perspective; discounting and horizon; utility methods; local costs; budget scope; templates; confidential information handling; and submission sequencing. Do not assume identical methods across countries, across committees or across technologies.
Pricing evidence: distinguish a value argument from an asking price
Develop price scenarios from the evidence-supported clinical claim, uncertainty, local economic implications and applicable commercial rules. Separate the company’s proposed price from observed prices, modeled net assumptions and legally agreed terms. International reference pricing and tender rules, where relevant, require a separate current country assessment; there is no universal reference basket.
Test whether the value case remains coherent under plausible comparator prices, shorter benefit duration or narrower eligibility. A model cannot compensate for a clinically unsupported claim by adjusting favorable assumptions. Ensure clinical, economic and commercial teams use the same population, treatment duration and evidence cut-off. 4 Economic evaluation Section 3 Economic evaluation
Managed access and outcomes-based agreements need operational evidence
Where a local pathway permits an agreement, define what it addresses: price, expenditure risk, clinical uncertainty or implementation. A financial rebate may improve the modeled economics but does not establish that long-term benefit exists. An outcomes-based agreement needs measurable outcomes, appropriate data access, responsibilities and feasible follow-up.
As a proposed readiness test, document eligibility, baseline, outcome definition, assessment timing, missing-data rules, reconciliation, payment adjustment, reassessment and exit conditions. Check legal and privacy requirements. Do not present a contract as evidence generation unless its design can actually answer the specified question.
Create one evidence spine with controlled local modules
A global value dossier can organize disease burden, unmet need, systematic evidence, clinical claims, models and sources. It is a reusable evidence asset—not a substitute for a local submission. Track each claim to its source and identify where the target comparator or population changes.
| Reusable core | Local module | Control to retain |
|---|---|---|
| Clinical studies and systematic review | Country decision scope and comparator mapping | Evidence version and applicability rationale |
| Conceptual economic model | Local methods, costs, utilities and assumptions | Model change log and validation |
| Disease and pathway evidence | Local epidemiology, diagnostics and access restrictions | Source dates and local expert review |
| Core value messages | Locally permissible, evidence-supported claims | Medical/legal/compliance approval as applicable |
| Evidence gaps | Country advice, further studies and reassessment | Accountable owner, deadline and evidence gate |
AI may help organize sources or compare requirements, but generated citations and extracted assumptions require verification. Qualified clinical, HEOR, regulatory and access reviewers should own conclusions and external commitments. This is a recommended governance approach, not a claim that a named platform has validated every function.
Hypothetical example: the same medicine, different access questions
A company has a new therapy with comparative trial evidence and immature long-term follow-up. Its global model assumes persistent benefit. One market prioritizes added benefit against a specified treatment; another needs a local cost-utility analysis; a third highlights eligible-population and near-term expenditure uncertainty.
The team preserves one source-controlled clinical core, revisits comparator relevance for each decision, tests treatment-effect waning and localizes costs and utilization. It does not claim the trial proves lifetime benefit or that a favorable decision in one market guarantees another. If a managed pathway is available, it evaluates whether proposed evidence collection could resolve the material gap. No outcome or commercial result is asserted; this example is illustrative.
A 90-day evidence-alignment roadmap
| Planning window | Proposed deliverable | Decision gate |
|---|---|---|
| Days 1–30 | Priority market map; decision questions; comparator/claim matrix; evidence gaps | Is the proposed clinical value claim supportable? |
| Days 31–60 | Model review; local-methods register; population and budget scenarios | Which uncertainty changes access or price feasibility? |
| Days 61–90 | Localized dossier modules; review sign-offs; advice and evidence plan | Are data, assumptions and implementation ready for the next interaction? |
These are planning windows, not guaranteed access timelines. Measure source-verified claim coverage, overdue assumptions, unresolved critical evidence gaps, model validation findings and post-review corrections. Treat rapid dossier production as secondary to decision relevance and evidence integrity.
HERMS perspective: connect value evidence to access execution
HERMS positions VALTRIX around clinical and value evidence, VALTIRA around pricing, HTA and budget impact, PACTRIX around access-agreement obligations and TENDRIX around tender decisions. These are company descriptions, not independently validated performance or acceptance claims. A relevant evaluation should demonstrate how the proposed workflow maintains evidence provenance, explicit assumptions and accountable approvals. AI Life Sciences Software | 25 HERMS Solutions
Explore HERMS pricing, HTA and market access solutions to discuss a demonstration focused on your clinical claim, local evidence gaps and access scenario.
Frequently asked questions
What is pharmaceutical market access?
It is the evidence, policy, pricing, reimbursement and implementation work connecting an authorized medicine to funded practical use. The pathway depends on the country and payer. Marketing authorization, an HTA recommendation, a negotiated price and a procurement award are distinct milestones—not interchangeable proof of access. Overview — Health Technology Assessment Transparency Committee Reimbursement Review Reports
How does clinical value connect to price?
Clinical evidence supports a comparative benefit claim. Local assessment, economic evidence, uncertainty, applicable pricing rules and negotiation determine how that claim may inform commercial terms. A statistically significant result does not automatically justify a premium, and a proposed price is not proof of value. 4 Economic evaluation Benefit Assessment of Medicinal Products Transparency Committee
What is the difference between cost-effectiveness and budget impact?
Cost-effectiveness concerns incremental costs relative to outcomes; budget impact concerns financial consequences for a defined payer population and period. A high-value intervention may still require substantial funding. Build separate but consistent analyses rather than treating a favorable ICER as an affordability assessment. Section 3 Economic evaluation Section 4 Use of the medicine in practice
Does EU JCA create one European reimbursement decision?
No. JCA supplies shared clinical analysis supporting national HTA. It does not set a single European price or remove local economic and reimbursement decisions. Companies still need country-specific planning, relevant comparators and transparent treatment of evidence gaps. Joint clinical assessments for medicinal products Overview — Health Technology Assessment
Can a global value dossier be used unchanged everywhere?
It can supply a controlled evidence core, but local comparators, methods, costs, population, templates and funding pathways need adaptation. Keep a change log and verify current local guidance. Currency conversion alone does not make a model or value claim suitable for another health system. NICE technology appraisal and highly specialised technologies guidance: the manual 4 Economic evaluation Section 3 Economic evaluation
Can real-world evidence resolve uncertainty?
It can inform selected questions if the data and design fit the decision. It cannot automatically remove confounding, establish missing clinical outcomes or substitute for all required evidence. Specify the uncertainty and proposed study before promising that future routine-care data will resolve it.
What matters most for cell and gene therapy access?
Often the key issues include comparative benefit, durability, long-term uncertainty, appropriate service delivery and budget consequences. Their relative importance is product- and country-specific. Avoid assuming a single-arm trial, one-time payment or outcomes agreement by itself establishes a complete value case. Joint clinical assessments for medicinal products 4 Economic evaluation
How should access teams measure readiness?
Use transparent decision metrics: evidence supporting each claim, comparator coverage, current local requirements, validated model assumptions, unresolved uncertainty and implementation feasibility. Include the quality of review and corrections, not only submission speed or number of documents generated.
Global access strategy is strongest when the clinical claim, economic model, budget forecast and local pathway tell the same defensible story. The objective is not the broadest possible value claim; it is a relevant claim that the evidence can withstand, supported by feasible funding and delivery.
Discuss your evidence-to-access priorities through HERMS Solutions , or explore related HERMS market access insights .
Sources and further reading
- Joint clinical assessments for medicinal products
- NICE technology appraisal and highly specialised technologies guidance: the manual
- Reimbursement Review Reports
- Section 3 Economic evaluation
- Overview — Health Technology Assessment
- Transparency Committee
- 4 Economic evaluation
- Benefit Assessment of Medicinal Products
- Section 4 Use of the medicine in practice
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026
Explore the pharmaceutical AI series
- AI decision authority and human oversight
- Agentic versus generative AI in pharmaceuticals
- AI governance in life sciences
- Human approval controls for pharmaceutical AI
- Real-world evidence for regulatory and market access
- AI medical device validation and change control
Explore HERMS life sciences solutions and AI governance and traceability, or request a workflow-focused demonstration.
Relevant HERMS solutions
Explore the HERMS solutions relevant to this article and assess their fit for your workflow, evidence and approval requirements.
